moderna rsv vaccine | Overview of Moderna’s Investigational RSV Vacc

Keyword	CPC	PCC	Volume	Score	Length of keyword
moderna rsv vaccine	1.63	0.3	6885	95	19
moderna	0.68	1	7069	95	7
rsv	1.23	0.7	5995	59	3
vaccine	0.3	0.3	8071	95	7

Keyword	CPC	PCC	Volume	Score
moderna rsv vaccine	1.2	0.1	3385	70
moderna rsv vaccine approval	1.42	1	1777	47
moderna rsv vaccine study	0.56	1	3348	71
moderna rsv vaccine efficacy	0.95	0.7	6182	96
moderna rsv vaccine fda approval	0.91	0.8	2527	52
moderna rsv vaccine data	0.42	0.9	988	20
moderna rsv vaccine uk	0.62	1	2211	13
moderna rsv vaccine 2024	0.99	0.8	972	39
moderna rsv vaccine phase 3	1.06	1	1417	67
moderna rsv vaccine fda	1.05	0.3	6738	50
moderna rsv vaccine 2023	1.57	0.8	1189	28
moderna rsv vaccine news	0.39	0.3	5150	80
moderna rsv vaccine canada	1.96	1	8841	26
moderna rsv vaccine submission	1.76	0.6	4723	57
moderna rsv vaccine approval 2024	1.63	0.2	7272	35
moderna rsv mrna vaccine	0.98	0.8	545	31
does moderna have a rsv vaccine	1.26	0.9	1372	50

Search Results related to moderna rsv vaccine on Search Engine

Overview of Moderna’s Investigational RSV Vaccine (mRNA …
cdc.gov

https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2024-02-28-29/02-RSV-Adults-Das-508.pdf

WEBOverview of mRNA-1345, Moderna’s investigational RSV vaccine. Pivotal Phase 2/3 trial. Efficacy. Safety. Immunogenicity. Persistence of antibody and revaccination – Phase 1 trial. Concomitant administration with influenza and COVID-19 vaccines.

DA: 65 PA: 90 MOZ Rank: 60

Investigational mRNA Vaccines & Respiratory Syncytial Virus - Moderna
modernatx.com

https://www.modernatx.com/media-center/all-media/blogs/Vaccines-Respiratory-Syncytial-virus

WEBToday we announced positive top-line data from our pivotal Phase 3 study of mRNA-1345, our investigational vaccine candidate against respiratory syncytial virus (RSV), in older adults. RSV is a common seasonal virus that can cause serious illness in certain vulnerable groups.

DA: 12 PA: 46 MOZ Rank: 74

Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older …
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa2307079

WEBDec 13, 2023 · The mRNA-1345 vaccine (Moderna) uses the same preF antigen and is based on the mRNA vaccine platform that was previously shown to be effective in addressing the worldwide burden of severe...

DA: 63 PA: 30 MOZ Rank: 91

Moderna Announces mRNA-1345, an Investigational Respiratory …
modernatx.com

https://news.modernatx.com/news/news-details/2023/Moderna-Announces-mRNA-1345-an-Investigational-Respiratory-Syncytial-Virus-RSV-Vaccine-Has-Met-Primary-Efficacy-Endpoints-in-Phase-3-Trial-in-Older-Adults/default.aspx

WEBJan 17, 2023 · mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults. mRNA-1345 was generally well-tolerated, with no safety concerns identified by the DSMB. Based on these results, Moderna intends to submit mRNA-1345 for regulatory approval.

DA: 25 PA: 67 MOZ Rank: 68

Moderna Advances Multiple Vaccine Programs to Late-Stage …
modernatx.com

https://news.modernatx.com/news/news-details/2024/Moderna-Advances-Multiple-Vaccine-Programs-to-Late-Stage-Clinical-Trials/default.aspx

WEBMar 27, 2024 · Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials. News Details. View All News. Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials. March 27, 2024. Download. Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpoints.

DA: 10 PA: 99 MOZ Rank: 3

Moderna Announces Global Regulatory Submissions For Its …
modernatx.com

https://news.modernatx.com/news/news-details/2023/Moderna-Announces-Global-Regulatory-Submissions-For-Its-Respiratory-Syncytial-Virus-RSV-Vaccine-MRNA-1345/default.aspx

WEBJul 5, 2023 · mRNA-1345 is an investigational RSV vaccine that consists of a single mRNA sequence encoding for a stabilized prefusion F glycoprotein. The vaccine uses the same lipid nanoparticles (LNPs) as in the Moderna COVID-19 vaccines. The F glycoprotein is on the surface of the virus and is required for infection by helping the virus to enter host cells.

DA: 91 PA: 10 MOZ Rank: 45

‘A good day’: FDA approves world’s first RSV vaccine - Nature
nature.com

https://www.nature.com/articles/d41586-023-01529-5

WEBMay 3, 2023 · Biotechnology company Moderna in Cambridge, Massachusetts, has an mRNA-based vaccine for preventing RSV in adults in the same age group under expedited review at the agency. Moreover, an FDA...

DA: 3 PA: 57 MOZ Rank: 14

Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in …
nejm.org

https://www.nejm.org/doi/pdf/10.1056/NEJMoa2307079

WEBA single dose of the mRNA-1345 vaccine resulted in no evident safety concerns and led to a lower incidence of RSV-associated lower respiratory tract disease and of RSV-associated acute...

DA: 30 PA: 27 MOZ Rank: 86

mRNA vaccine effective against RSV respiratory disease - Nature
nature.com

https://www.nature.com/articles/d41591-023-00017-7

WEBFeb 15, 2023 · Moderna has announced topline results for its mRNA-based vaccine against respiratory syncytial virus (RSV) infection in adults 60 years of age and older. mRNA-1345 targets the RSV...

DA: 2 PA: 87 MOZ Rank: 94

Moderna's RSV vaccine for older adults 84% effective and safe
umn.edu

https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/modernas-rsv-vaccine-older-adults-84-effective-and-safe-clinical

WEBDec 14, 2023 · Today, researchers from Moderna and around the globe report positive phase 2/3 results for its experimental respiratory syncytial virus (RSV) vaccine for people 60 years and older, with an efficacy of 83.7% and a good safety profile.

DA: 20 PA: 67 MOZ Rank: 46